Basilea Pharmaceutica (0QNA) Share Price & Analysis
0QNA Stock Chart & Stats
- Day’s Range
- CHF 70.60 - CHF 71.40
- 52-Week Range
- CHF 44.70 - CHF 74.30
- Previous Close
- CHF 73.10
- Volume
- N/A
- Average Volume (3M)
- 1,149
- Market Cap
- CHF 871.17M
- Enterprise Value
- CHF 644.92M
- Total Cash (Recent Filing)
- CHF 175.98M
- Total Debt (Recent Filing)
- CHF 83.44M
- Price to Earnings (P/E)
- 16.6
- Beta
- 0.64
- Next Earnings
- Feb 16, 2027 (Est.)
- EPS Estimate
- 2.88
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Commercial Growth And High Margins
Strong 2025 revenue acceleration alongside consistently high gross margins indicates improving commercial traction and attractive product economics. If maintained, this combination can support operating leverage, fund internal development, and strengthen Basilea’s ability to reinvest in its specialty-medicine portfolio.
Robust Cash Generation
Positive operating and free cash flow, with operating cash flow exceeding net income, demonstrates that recent earnings are converting into liquidity. This provides internally generated funding for research, commercialization, and obligations while reducing reliance on external capital over the medium term.
Advancing Late-stage Pipeline
Progression of two assets toward Phase III creates potential for additional products beyond the current commercial base. A maturing late-stage pipeline can broaden future revenue sources, improve portfolio durability, and provide multiple opportunities for partnering or eventual commercialization.
Bears Say
Profitability Volatility
The sharp change in net margin shows that reported profitability remains sensitive to product mix, milestones, or other variable items. Such volatility makes earnings power less predictable and can constrain the company’s ability to plan investment and allocate cash consistently.
Clinical And Regulatory Execution Risk
Key pipeline value depends on successful trials, regulatory alignment, and timely filings, yet important decisions and readouts remain ahead. Delays or changed study requirements could postpone commercialization, extend development spending, and defer the revenue contribution expected from these programs.
Convertible Bond Maturity
The approaching convertible maturity creates a defined financing obligation that could absorb cash or require refinancing. Even with improved liquidity, meeting this obligation may limit capital available for clinical development, commercialization, or other strategic priorities during the planning period.
Basilea Pharmaceutica News
0QNA FAQ
What was Basilea Pharmaceutica’s price range in the past 12 months?
What is Basilea Pharmaceutica’s market cap?
When is Basilea Pharmaceutica’s upcoming earnings report date?
How were Basilea Pharmaceutica’s earnings last quarter?
Is Basilea Pharmaceutica overvalued?
Does Basilea Pharmaceutica pay dividends?
What is Basilea Pharmaceutica’s EPS estimate?
How many shares outstanding does Basilea Pharmaceutica have?
What happened to Basilea Pharmaceutica’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Basilea Pharmaceutica?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Basilea Pharmaceutica
Basilea Pharmaceutica AG operates as a commercial-stage biopharmaceutical enterprise, concentrating its efforts on inventing and advancing treatments to address critical unmet medical needs within the therapeutic fields of oncology and anti-infectives. Its commercialized offerings include Cresemba, an azole antifungal drug available in both intravenous and oral formulations, utilized for managing invasive aspergillosis and mucormycosis in the United States and the European Union; this drug is also advancing through Phase III clinical trials in Japan for various invasive fungal infections. The company additionally provides Zevtera, an antibiotic targeting community and hospital-acquired pneumonia, which is also undergoing Phase III clinical development for acute bacterial skin and skin structure infections, along with Staphylococcus aureus bacteremia. Beyond its current portfolio, Basilea's pipeline features Derazantinib, a small molecule inhibitor in Phase 2 clinical trials for bile duct cancer, and in Phase 1/2 trials for both bladder and stomach cancers, as well as Lisavanbulin, a novel tumor checkpoint controller drug. Established in 2000, Basilea Pharmaceutica AG maintains its corporate headquarters in Basel, Switzerland.
- Sector
- General
- Industry
- Biotechnology
- CEO
- David Veitch
- Employees
- 200
- Website
- www.basilea.com
- Address
- Hegenheimermattweg 167b, Allschwil, BL, 4123, CH
Basilea Pharmaceutica (0QNA) Earnings & Revenues
0QNA Earnings Call
Earnings Call SentimentPositive
The call presented a strongly positive operational and financial picture: double-digit revenue growth, a materially higher operating profit, strengthened cash position, increased non-dilutive funding, and clear pipeline progression (two Phase III assets and new first-in-human study). Management raised full-year guidance and reiterated multi-year value creation (Agenda 2030). Key challenges are execution and timing risks around late-stage clinical readouts and regulatory clarity, increased R&D spend and near-term operating expense pressure, working capital timing effects on cash flow, and a convertible bond maturing in 2027. On balance, the positive commercial momentum, funding awards, guidance upgrades and pipeline advancement outweigh the near-term costs and timing uncertainties.
View all GB:0QNA earnings summaries0QNA Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 5 | 4 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 10 | 0 | 2 |
